Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > April 28, 2021, VOTE @ the Meeting ℹNO SHARE SPLIT

<< Previous

Bullboard Posts

Next >>

Comment by Bigginvestoron Apr 22, 2021 9:58am

121 Views

Post# 33043974

RE:RE:RE:RE:RE:RE:April 28, 2021, VOTE @ the Meeting ℹNO SHARE SPLIT

AngelaL wrote: What do you believe is the reason that the sp has not risen strongly after the recent solid PR's announcing the PAH in-licensing and the start of the Phase 1 trial?

reason I think they might be a buy out or RS coming

<< Previous

Bullboard Posts

Next >>

Pro Women’s Hockey League comes to NHL 25 in December